


| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | | | | Docket Number (Optional) 0107-03 | Application Number 09/873,952 | | |
|---|---|-----------------|-----------|--|---|-------------|----------------------------|
| | | | | Applicant(s) Reinhard Zeissig | | | |
| | | | | Filing Date 6/4/2001 | Group Art Unit | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| <i>h</i> | | 5,571,534 | 11/5/1996 | Jalonen et al. | 424 | 479 | |
| <i>h</i> | | 5,904,930 | 5/18/1999 | Fischer et al. | 424 | 448 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| REF | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | Translation | |
| | | | | | | YES | NO |
| <i>h</i> | 359,981 | 3/28/1990 | EPO | | | | |
| <i>h</i> | 152,379 | 8/21/1985 | EPO | | | | |
| <i>h</i> | 4,408,011 | 11/2/1995 | DE | | | | |
| <i>h</i> | 4,132,345 | 4/1/1993 | DE | | | | |
| | 4,408,011 | 11/2/1995 | DE | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| <i>h</i> | D. Arndt et al.: Alkylphospholipid Liposomes, Drugs of Today, 1998, 34 (Suppl. F), 83-96 R. Zeissig: Increase of the Antitumor Effect of liposomal octadecyl-piperidinyl-phosphate ... , XP-002136791 4/27/2000 L. D. Mayer et al.: The role of tumor assisted macrophages in the delivery of liposomal doxorubicin, J.Pharmacol. and Experimental Therapeutics, 280, No. 3, 1406-1414 D. Arndt et al., Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas, | | | | | | |
| <i>h</i> | Breast Cancer Research and Treatment, 43, 237-246, 1997 B.S. Katzenellenbogen et al.: Antiestrogens: Mechanism of action and resistance in breast cancer, Breast Cancer Research and Treatment, 44, 22-38, 1997 C. K. Osborne: Tamoxifen in the treatment of breast cancer, Drug Therapy, 339, No. 22, 1609-1618, 1998 | | | | | | |
| EXAMINER <i>h</i> | | | | DATE CONSIDERED <i>3/03</i> | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Initials of the Examining Attorney and the Date of Filing
Initials of the Patent Application Examiner and the Date of Filing

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|------------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | <i>Complete if Known</i> | |
| | | Application Number | 09/873,952 |
| | | Filing Date | June 4, 2001 |
| | | First Named Inventor | Reinhard Zeisia et al. |
| | | Art Unit | |
| | | Examiner Name | |
| Sheet | 1 | of | 2 |
| | | Attorney Docket Number | 0107-032 |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS


| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | |
| | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



B1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2 of 2

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 09/873,952 |
| Filing Date | June 4, 2001 |
| First Named Inventor | Reinhard Zeisig et al. |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 0107-032 |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|-------------------|------------|--|----------------|
| W | | SPRUB, ET AL., Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models; J Cancer Res Clin Oncol (1993) 119:142-140 | |
| W | | HOTTKOWITZ, ET AL., Experimental Therapeutics; Proceedings of the American Association for Cancer Research, Volume 37, March 1996 | |

Examiner
Signature

Date
Considered

3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.